Bayer Pharma Aktiengesellschaft

Bayer Animal Health Gmbh

Nicole Schmidt

Ulf Bömer

Nicholas Charles Ray

Andrea Rotgeri

Ulrich Bothe

Judith Günther

Jens Nagel

Martin Lange

Holger Siebeneicher

Jürgen Klar

Christian Stegmann

Adam James Davenport

Peter Hauff

Stefan Baeurle

Reinhard Nubbemeyer

Holger Steuber

Alexandra Rausch

Christian Friedrich

Andreas Sutter

Thomas Dyrks

Juergen Klar

Ina Groeticke

Ina Gröticke

Stefan Bäurle

Gerald Beddies

Pascal Savy

Maria De Lourdes Mottier

Ulf Boemer

Stefan Joachim Jodl

Adrian Foster

Jörn Krätzschmar

Judith Gunther

The present application relates to the use of substituted indazoles for treatment and/or prophylaxis of allergic and/or inflammatory diseases in animals, especially for treatment and/or prophylaxis of atopic dermatitis, Flea Allergy Dermatitis, inflammatory bowel disease, osteoarthritis and inflammatory pain, non-infectious recurrent airway disease, insect hypersensitivity, asthma, respiratory disease, mastitis and endometritis in animals.

Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseases a sole agent or in combination with other active ingredients.

Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.

Carboxylic acid aromatic amides

The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).

Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a diseaseas a sole agent or in combination with other active ingredients.

Growing community of inventors

Wuppertal, Germany

Nicole Schmidt